TrialThe Lancet. Respiratory medicine2022

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial.

Benjamin A Fisher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.